secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2022-12-28T23:59:59+00:00
Accession:  0001104659-22-130566
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax closes $25.25M additional convertible note offering; total net proceeds $166.3M
--------------------------------------------------------------------------------

- $25.25M aggregate principal of 5.00% Convertible Senior Notes due 2027 sold to J.P. Morgan, Jefferies, Cowen on Dec 23.
- Total net proceeds from offering (including initial $142.2M on Dec 20) is $166.3M after discounts and expenses.
- Proceeds to fund Nuvaxovid launch, working capital, and possible repurchase of $325M 3.75% notes due Feb 1, 2023.
- Additional Notes issued under same indenture as initial notes; unregistered sale under Rule 144A and Section 4(a)(2).
- Discount to initial purchasers was approx $0.76M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922130566/0001104659-22-130566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922130566/tm2233439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-130566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer